Mobile health intervention for managing hypertension in ICH survivors
MOBILE Health Intervention in IntraCerebral Hemorrhage Survivors
NA · The University of Hong Kong · NCT05830305
This study is testing a mobile health program to see if it helps people who have survived a brain bleed manage their high blood pressure better than regular doctor visits.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | The University of Hong Kong (other) |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT05830305 on ClinicalTrials.gov |
What this trial studies
This randomized controlled trial evaluates the effectiveness and safety of a mobile health intervention aimed at managing hypertension in survivors of intracerebral hemorrhage (ICH). A total of 140 participants will be divided into two groups: one receiving the mobile health intervention, which includes daily blood pressure monitoring through the WeRISE app and regular follow-up calls for medication adjustments, and the other receiving standard care from their physicians. The study will track participants for 26 weeks to assess the control of hypertension at specified intervals. The intervention emphasizes education on hypertension management and lifestyle modifications, such as the DASH diet.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have been diagnosed with primary intracerebral hemorrhage and have a modified Rankin Scale score of 4 or less upon discharge.
Not a fit: Patients who may not benefit include those with severe comorbid conditions, significant cognitive impairments, or those unable to access or use the WeRISE app for monitoring.
Why it matters
Potential benefit: If successful, this intervention could significantly improve blood pressure control in ICH survivors, potentially reducing the risk of further complications.
How similar studies have performed: Other studies have shown promise in using mobile health interventions for chronic disease management, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Primary ICH Diagnosis * Age ≥ 18 years * Discharge Modified Rankin Scale of ≤4 Exclusion Criteria: * Expected life expectancy of \<1 year * Patient or caregiver does not have access to WeRISE App. * Patient or caregiver does not know how to use WeRISE App . * Inability to perform home BP monitoring * Inability to participate in follow-up activity * Contraindication for intensive and rapid lowering of blood pressure (Known \>70% cerebral vascular stenosis; History of fall, dizziness or syncope due to hypotension; Any other medical condition that is deemed contraindicated for low blood pressure * Bleeding tendency (Platelet count \< 75 x 10\^9/L; Known coagulation disorder) * Severe renal impairment (Estimated glomerular filtration rate using CKD-EPI formula \<30 ml/min/1.73m2) * Severe liver impairment (Child-Pugh C cirrhosis) * Known contraindication or allergy to two or more anti-hypertensive classes
Where this trial is running
Hong Kong
- Queen Mary Hospital — Hong Kong, Hong Kong (RECRUITING)
Study contacts
- Study coordinator: Kay Cheong Teo, MBBS
- Email: kcteo@hku.hk
- Phone: (852)22553749
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Intracerebral Hemorrhage, Hypertension